XML 100 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Segment reporting (Tables)
 12 Months Ended
Aug. 31, 2019
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated
The following table reflects results of operations of the Company's reportable segments (in millions):

 
For the years ending August 31,
 
2019
 
2018
 
2017
Sales:
 
 
 
 
 
Retail Pharmacy USA
$
104,532

 
$
98,392

 
$
87,302

Retail Pharmacy International
11,462

 
12,281

 
11,813

Pharmaceutical Wholesale
23,053

 
23,006

 
21,188

Eliminations1
(2,180
)
 
(2,142
)
 
(2,089
)
Walgreens Boots Alliance, Inc.
$
136,866

 
$
131,537

 
$
118,214

Adjusted Operating income:2
 
 
 
 
 
Retail Pharmacy USA
$
5,255

 
$
5,814

 
$
5,606

Retail Pharmacy International
747

 
929

 
939

Pharmaceutical Wholesale
939

 
936

 
922

Eliminations1
1

 

 

Walgreens Boots Alliance, Inc.
$
6,942

 
$
7,679

 
$
7,467

Depreciation and amortization:
 
 
 
 
 
Retail Pharmacy USA
$
1,459

 
$
1,196

 
$
1,090

Retail Pharmacy International
429

 
419

 
414

Pharmaceutical Wholesale
150

 
155

 
150

Walgreens Boots Alliance, Inc.
$
2,038

 
$
1,770

 
$
1,654

Capital expenditures:
 
 
 
 
 
Retail Pharmacy USA
$
1,323

 
$
1,022

 
$
860

Retail Pharmacy International
275

 
241

 
384

Pharmaceutical Wholesale
104

 
104

 
107

Walgreens Boots Alliance, Inc.
$
1,702

 
$
1,367

 
$
1,351
Reconciliation of operating profit (loss) from segments to consolidated
The following table reconciles adjusted operating income to operating income (in millions):
 
For the years ending August 31,
 
2019
 
2018
 
2017
Adjusted operating income2
$
6,942

 
$
7,679

 
$
7,467

Acquisition-related amortization and impairment3
(567
)
 
(448
)
 
(332
)
Transformational cost management
(477
)
 
—

 
—

Acquisition-related costs
(303
)
 
(231
)
 
(474
)
Adjustments to equity earnings in AmerisourceBergen
(233
)
 
(175
)
 
(187
)
Store optimization
(196
)
 
(100
)
 
—

LIFO provision
(136
)
 
(84
)
 
(166
)
Certain legal and regulatory accruals and settlements4
(31
)
 
(284
)
 
—

Asset recovery
—

 
15

 
11

Hurricane-related costs
—

 
(83
)
 
—

Cost Transformation
—

 
—

 
(835
)
Operating income2
$
4,998

 
$
6,289

 
$
5,484



1 
Eliminations relate to intersegment sales between the Pharmaceutical Wholesale and the Retail Pharmacy International segments.
2 
The Company adopted new accounting guidance in Accounting Standards Update 2017-07 as of September 1, 2018 (fiscal 2019) on a retrospective basis for the Consolidated Statements of Earnings presentation. See note 1, summary of major accounting policies, for further information.
3 
Includes impairment of $73 million for indefinite-lived pharmacy licenses intangible asset recorded during the three months ended August 31, 2019, in the Boots reporting unit within the Retail Pharmacy International segment.
4 
Beginning in the quarter ended August 31, 2018, management reviewed and refined its practice to include all charges related to the matters included in certain legal and regulatory accruals and settlements. This non-GAAP measure is presented on a consistent basis for fiscal year 2019.
Geographic data for net sales
Geographic data for sales is as follows (in millions):
 
2019
 
2018
 
2017
United States
$
104,532

 
$
98,392

 
$
87,302

United Kingdom
12,729

 
13,297

 
12,552

Europe (excluding the United Kingdom)
17,009

 
17,594

 
16,224

Other
2,597

 
2,254

 
2,136

Sales
$
136,866

 
$
131,537

 
$
118,214
Geographic data for long-lived assets
Geographic data for long-lived assets, defined as property, plant and equipment, is as follows (in millions):
 
2019
 
2018
United States
$
10,598

 
$
10,678

United Kingdom
2,162

 
2,458

Europe (excluding the United Kingdom)
521

 
576

Other
197

 
199

Total long-lived assets
$
13,478

 
$
13,911